A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
Egesta Lopci,Luca Toschi,Fabio Grizzi,Daoud Rahal,Laura Olivari,Giovanni Francesco Castino,Silvia Marchetti,Nina Cortese,Dorina Qehajaj,Daniela Pistillo,Marco Alloisio,Massimo Roncalli,Paola Allavena,Armando Santoro,Federica Marchesi,Arturo Chiti +15 more
TL;DR: The present study shows a direct association between metabolic parameters on FDG-PET with tissue expression of immune-checkpoints and disease-free survival (DFS) in resected NSCLC patients and finds a statistically significant correlation between SUVmax and SUVmean.
Journal ArticleDOI
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Alessandra Bearz,I. Garassino,Marcello Tiseo,Orazio Caffo,Hector Soto-Parra,Massimo Boccalon,Renato Talamini,Armando Santoro,Marco Bartolotti,V. Murgia,Massimiliano Berretta,Umberto Tirelli +11 more
TL;DR: The good tolerability of Pemetrexed even in patients with advanced NSCLC and brain metastases is demonstrated, and a very good overall response rate with evidence of activity on brain localizations is found.
Journal ArticleDOI
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
Giuseppe Visani,Lara Malerba,Pietro Maria Stefani,Saveria Capria,Piero Galieni,Francesco Gaudio,Giorgina Specchia,Giovanna Meloni,Filippo Gherlinzoni,Claudio Giardini,Sadia Falcioni,Francesca Cuberli,Marco Gobbi,Barbara Sarina,Armando Santoro,Felicetto Ferrara,Marco B. L. Rocchi,Enrique M. Ocio,Maria Dolores Caballero,Alessandro Isidori +19 more
TL;DR: The new BeEAM regimen is safe and effective for heavily pretreated lymphoma patients and 4 of 43 patients achieved the first complete remission after receiving the high-dose therapy with autologous stem cell transplantation.
Journal ArticleDOI
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Bohuslav Melichar,P. Koralewski,Alain Ravaud,A. Pluzanska,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,M. Filipek,Remy Delva,Emmanuel Sevin,Sylvie Negrier,Joseph McKendrick,Armando Santoro,P. Pisa,Bernard Escudier +14 more
TL;DR: This retrospective subgroup analysis suggests that the dose of IFN can be reduced to manage side-effects while maintaining efficacy in patients with mRCC receiving bevacizumab + IFN.
Journal ArticleDOI
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Paolo Andrea Zucali,Tommaso De Pas,Giovannella Palmieri,Adolfo Favaretto,Antonio Chella,Marcello Tiseo,Michele Caruso,Matteo Simonelli,Matteo Perrino,Fabio De Vincenzo,Francesca Toffalorio,Vincenzo Damiano,Giulia Pasello,Erika Garbella,M. Ali,Fabio Conforti,Margaret Ottaviano,Angela Cioffi,Sabino De Placido,Laura Giordano,Monica Bertossi,Annarita Destro,Luca Di Tommaso,Armando Santoro +23 more
TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.